RxSight Inc. (RXST) expects fourth quarter 2025 revenue to be around $32.6 million, surpassing analysts’ estimates of $27.53 million. Preliminary unaudited fiscal year 2025 revenue is projected to be approximately $134.5 million, exceeding previous guidance. The company has appointed Mark Wilterding as Chief Financial Officer, bringing over 25 years of financial leadership experience to the role. Audited full-year 2025 financial results and full-year 2026 guidance will be disclosed in February alongside the fourth quarter earnings release.

Read more at Nasdaq: RxSight Sees Q4 Revenue Above View; Names Mark Wilterding CFO